Enveda is an AI-driven drug discovery company that reads nature's untapped chemistry through metabolomics and machine learning to discover small-molecule medicines roughly four times faster than the industry average. Its pipeline spans obesity and metabolic disease, immunology and inflammation, fibrosis and neurosensory disorders, and the company has raised more than $845 million since 2019.
The Series E is intended to pave the way for a future IPO
Advance three medicines into late-stage development with Series E proceeds
Potential public listing
Enveda, which is working on an “exercise in a tablet” oral obesity candidate, has collected $311 million in a Series E crossover round to support the advancement of three medicines into late-stage development.
Founder and Chief Executive Officer
Chief Technology Officer
Chief Scientific Officer
Chief Financial Officer